Anagliptin vs Cofrogliptin

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Type 2 Diabetes

Shared mechanism: DPP-4 · full Type 2 Diabetes pipeline

Anagliptin · Suiny

Marketed by Sanwa Kagaku Kenkyusho and partners

Phase 3 in Type 2 Diabetessmall molecule
Partial signal

NCT01529541 · Phase 3 · completed

The study randomly assigned an estimated 200 participants and used triple masking with sitagliptin as an active comparator. Its primary endpoint was the change in HbA1c, a surrogate measure, and no primary-outcome result is available to show whether the comparison was favorable.

Next expected readout: March 2027 · NCT07442006 (registry estimate)

Reported efficacy

The Change in HbA1c from baseline to week24 (0wk, 8wk, 16wk, 24wk): HbA1c change from baseline to Week 24: anagliptin 100 mg -0.50±0.45%, anagliptin 200 mg -0.51±0.55%, placebo +0.23±0.62% (n=37/33/39, baseline HbA1c 7.14±0.69%); described as significant reductions vs placebo. (met)

Result source: NCT01529528

Cofrogliptin

Marketed by Haisco Pharmaceutical Group

Phase 3 in Type 2 Diabetessmall molecule
Reliable signal

NCT04556851 · Phase 3 · completed

This randomized, double-blind, placebo-controlled trial enrolled 476 patients and measured change in HbA1c, a standard efficacy measure in diabetes, at 24 weeks. Both HSK7653 doses lowered HbA1c significantly more than placebo (p<0.0001), meeting the trial's primary goal.

Next expected readout: June 2027 · NCT07122102 (registry estimate)

Reported efficacy

HbA1c Change From Baseline at Week 24 (Baseline and week 24): HbA1c change from baseline to week 24 (LS mean, SE): cofrogliptin (HSK7653) 10 mg -0.96% (0.063), 25 mg -0.99% (0.064), linagliptin 5 mg -1.07% (0.065); non-inferiority margin of 0.4% met for both cofrogliptin doses vs linagliptin (met)

Result source: NCT04564872

Results for Type 2 Diabetes

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointAnagliptinCofrogliptin
HbA1c, change-0.5% vs 0.2%a−0.7 vs placeboanagliptin 200 mg · wk 24NCT01529528
2 other results
  • -0.5% vs 0.2% anagliptin 100 mg · wk 24 · Phase 3 · primary NCT01529528
  • -0.8% vs -0.8% wk 24 · Phase 3 · primary NCT01529541
-1.0% vs -1.1%avs linagliptin 5 mgcofrogliptin (HSK7653) 25 mg · wk 24NCT04564872
1 other result
  • -1.0% vs -1.1% cofrogliptin (HSK7653) 10 mg · wk 24 · Phase 3 · primary NCT04564872
Body weight, change (kg)—Not posted · NCT01529528—Not posted · NCT04564872
HbA1c below 7%—Not posted · NCT01529528—Not posted · NCT04564872
Fasting plasma glucose, change—Not posted · NCT01529528—Not posted · NCT04564872
3-point MACE (% with event)—Not posted · NCT01529528—Not posted · NCT04564872

HbA1c, change

Anagliptin
-0.5% vs 0.2%a−0.7 vs placeboanagliptin 200 mg · wk 24NCT01529528
2 other results
  • -0.5% vs 0.2% anagliptin 100 mg · wk 24 · Phase 3 · primary NCT01529528
  • -0.8% vs -0.8% wk 24 · Phase 3 · primary NCT01529541
Cofrogliptin
-1.0% vs -1.1%avs linagliptin 5 mgcofrogliptin (HSK7653) 25 mg · wk 24NCT04564872
1 other result
  • -1.0% vs -1.1% cofrogliptin (HSK7653) 10 mg · wk 24 · Phase 3 · primary NCT04564872

Body weight, change (kg)

Anagliptin
—Not posted · NCT01529528
Cofrogliptin
—Not posted · NCT04564872

HbA1c below 7%

Anagliptin
—Not posted · NCT01529528
Cofrogliptin
—Not posted · NCT04564872

Fasting plasma glucose, change

Anagliptin
—Not posted · NCT01529528
Cofrogliptin
—Not posted · NCT04564872

3-point MACE (% with event)

Anagliptin
—Not posted · NCT01529528
Cofrogliptin
—Not posted · NCT04564872
  1. a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
  2. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  3. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Cofrogliptin

HbA1c -0.59% @ 24wk25 mg
absolute change · percentage points
No placebo or comparator arm
NCT04556851 · Phase 3 · sponsor-reported, not registry data
show 1 more result
-0.63% @ 24wkcofrogliptin (HSK7653) 10 mg
NCT04556851 · Phase 3 · sponsor-reported, not registry data

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Anagliptin's landscape · Cofrogliptin's landscape